Please login to the form below

Not currently logged in
Email:
Password:

Plavix

This page shows the latest Plavix news and features for those working in and with pharma, biotech and healthcare.

AZ's Brilinta disappoints in stroke trial

AZ's Brilinta disappoints in stroke trial

superiority to Sanofi's Plavix (clopidogrel), a former blockbuster now subject to generic competition.

Latest news

  • FDA gives the nod to TMC's antiplatelet drug FDA gives the nod to TMC's antiplatelet drug

    into a market formerly dominated by Sanofi's Plavix (clopidogrel) which lost patent protection in 2012. ... In a trial that compared Kengreal to Plavix in more than 10, 000 participants, TMC's significantly reduced the occurrence of heart attack, the

  • Heart drug sales continue downward spiral Heart drug sales continue downward spiral

    Sanofi has a number of CV medicines including Aprovel (irbesartan), Lovenox (enoxaparin) and the co-marketed Plavix (clopidogrel), which collectively made the firm 4.2bn euro ($4.7bn) last year, helping

  • FDA reviewer backs approval of TMC's cangrelor FDA reviewer backs approval of TMC's cangrelor

    FDA reviewer backs approval of TMC's cangrelor. Claims it offers a small benefit over Sanofi’ s Plavix. ... the multibillion-dollar market formerly occupied by Sanofi's Plavix (clopidogrel) which lost patent protection in 2012.

  • AZ’s Brilinta clears cardiovascular outcomes trial AZ’s Brilinta clears cardiovascular outcomes trial

    Brilinta was first launched in 2011 as potential successor to Sanofi's formerly $7bn-a-year antiplatelet brand Plavix (clopidogrel), which saw its sales decimated by generic competition after key patents

  • AZ seeks leg up in antiplatelet market with Brilinta antidote AZ seeks leg up in antiplatelet market with Brilinta antidote

    blockbuster Plavix (clopidogrel), which saw its sales pummelled by generic competition after key patents expired in 2012. ... Now it has started focusing on the benefits of its drug versus Plavix and its generics, including a 21% reduction in

More from news
Approximately 3 fully matching, plus 117 partially matching documents found.

Latest Intelligence

  • Who tops the pharma list? Who tops the pharma list?

    BMS' departure from the 2012 top 10 was driven by the patent expiries of the hypertension drug, Avapro - which had 2011 sales of $2.2bn - and Plavix. ... The latter, an antiplatelet agent it co-marketed with Sanofi, enjoyed 2011 sales of $9.4bn - but,

  • Drug pricing in Ireland Drug pricing in Ireland

    Some, like Lipitor and Plavix, have already come off patent – with damaging fiscal repercussions for both the country and the companies alike.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Hanspeter Spek to retire from Sanofi Hanspeter Spek to retire from Sanofi

    During his time at Sanofi, he has helped with the success of several significant products, including bloodthinner Plavix, insulin Lantus and cancer drug Taxotere.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics